Ibutamoren (MK-677)

Research-Grade

Ibutamoren mesylate (MK-677) is an orally bioavailable, non-peptide growth hormone secretagogue developed by Merck in the 1990s. Despite being discussed alongside peptides in the GH optimization space, Ibutamoren is a small molecule — a spiroindoline compound — that acts as a potent, selective agonist of the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor). Its key advantage over injectable peptide secretagogues like Ipamorelin or GHRP-6 is oral bioavailability: a single daily capsule produces sustained, dose-dependent increases in GH pulsatility and IGF-1 levels lasting 24 hours. Ibutamoren has been studied in multiple randomized controlled trials across diverse populations: elderly adults with hip fractures, obese individuals, growth hormone-deficient subjects, and healthy young men. In a landmark 2-year RCT in elderly subjects, daily MK-677 (25 mg) increased IGF-1 levels to those of healthy young adults, improved body composition (increased fat-free mass, decreased visceral fat), and enhanced certain measures of functional capacity. Sleep architecture studies have shown that MK-677 increases stage IV (deep sleep) duration by approximately 50% and REM sleep by 20%, likely mediated through its effects on the GH-ghrelin axis. However, Ibutamoren also raises cortisol modestly, increases appetite substantially (via ghrelin-pathway activation), and can impair insulin sensitivity with chronic use — side effects that distinguish it from more selective peptide secretagogues. Fasting glucose and HbA1c should be monitored in long-term users. Despite reaching Phase II clinical trials for multiple indications, MK-677 was never granted FDA approval and remains a research compound.